AC Immune SA FCF yield
Was ist das FCF yield von AC Immune SA?
FCF yield von AC Immune SA ist -55.97%
Was ist die Definition von FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu AC Immune SA
Was macht AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Unternehmen mit fcf yield ähnlich AC Immune SA
- Leveljump Healthcare hat FCF yield von -56.23%
- Organic Garage hat FCF yield von -56.17%
- China Power International Development hat FCF yield von -56.16%
- Kintara Therapeutics hat FCF yield von -56.10%
- Helix Resources hat FCF yield von -56.06%
- ENDRA Life Sciences Inc hat FCF yield von -56.05%
- AC Immune SA hat FCF yield von -55.97%
- Universal Copper hat FCF yield von -55.95%
- Marathon Gold hat FCF yield von -55.93%
- Rex Resources hat FCF yield von -55.92%
- InMed Pharmaceuticals hat FCF yield von -55.87%
- Surge Battery Metals hat FCF yield von -55.83%
- Pressure BioSciences hat FCF yield von -55.71%